Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 3/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28516922 | 0.87 | PIK3CA (0.36) | USP30PIK3CAUSP2SMN1; SMN2KDM1A | |
| SCHEMBL23671531 | 0.85 | NOTUM (0.32) | NOTUM | |
| SCHEMBL2123391 | 0.80 | PIK3CA (0.41) | USP30PIK3CAUSP2SMN1; SMN2PIK3R1 | |
| SCHEMBL22471426 | 0.80 | PIK3CA (0.40) | USP30PIK3CAUSP2SMN1; SMN2KDM1A | |
| SCHEMBL29966436 | 0.80 | PIK3CA (0.40) | USP30PIK3CAUSP2SMN1; SMN2KDM1A | |
| SCHEMBL5959175 | 0.78 | NOTUM (0.40) | USP30PIK3CAUSP2SMN1; SMN2KDM1A | |
| SCHEMBL28373181 | 0.77 | USP30 (0.34) | USP30PIK3CAUSP2SMN1; SMN2DPP4 | |
| SCHEMBL29966823 | 0.75 | DPP4 (0.33) | USP30PIK3CARORCDPP4 | |
| SCHEMBL30898670 | 0.72 | NOTUM (0.53) | USP2SMN1; SMN2KDM1ANOTUM | |
| SCHEMBL15676941 | 0.72 | NOTUM (0.53) | USP2SMN1; SMN2KDM1ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | UCBBiopharma Srl (BE) | 2022-10-04 | — | — | US | disclosed |
| CN-112334192-A | Spirocyclic indane analogs as IL-17 modulators | UCB生物制药有限责任公司 | 2021-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | IL17A, IL18, IL23R | USP30 4658/4885PIK3CA 3697/4885USP2 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.